People living with narcolepsy who develop cataplexy and excessive daytime sleepiness have a new treatment called Xywav, from Jazz Pharmaceuticals.
Jazz Pharmaceuticals NEWS
On July 21, 2020 the U.S. FDA approved Jazz Pharmaceuticals’ (JAZZ) product Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Narcolepsy is a chronic, debilitating neurological disorder characterized by EDS and an inability to normally regulate sleep-wake cycles. It affects an estimated one in 2,000 people in the United States with symptoms typically appearing in childhood or adolescence. Studies have shown it may take 10 years or more for people with narcolepsy to receive a diagnosis. The five main symptoms of narcolepsy include: EDS, cataplexy, disturbed nighttime sleep, sleep-related hallucinations and sleep paralysis. Narcolepsy is associated with obesity, hypertension, diabetes and hypercholesterolemia.